Hillevax

Hillevax Rule of 40

Delisted

Rule of 40 of Hillevax (HLVX) as of Nov 20, 2026.

Rule of 40

-

Last updated:

Rule of 40 of Hillevax is 2026 - . Rule of 40 of Hillevax was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hillevax Stock analysis

What does Hillevax do? HilleVax, Inc. develops and commercializes novel vaccines, focusing on HIL-214, a bivalent virus-like particle (VLP) vaccine candidate for norovirus-induced acute gastroenteritis. The vaccine combines VLPs for norovirus genotypes GI.1 and GII.4 with an aluminum hydroxide adjuvant to enhance immune response. HIL-214 targets moderate-to-severe cases of norovirus infection, which causes symptoms like diarrhea, vomiting, and dehydration. The company's primary revenue stream will come from the future commercialization of HIL-214 after regulatory approval, with potential sales to healthcare providers and public health programs. Hillevax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hillevax stock

On Eulerpool you can find the complete historical development of Rule of 40 Hillevax since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Hillevax

All Key Metrics — Hillevax